1. Home
  2. ERC vs OTLK Comparison

ERC vs OTLK Comparison

Compare ERC & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Multi-Sector Income Fund

ERC

Allspring Multi-Sector Income Fund

SELL

Current Price

$8.16

Market Cap

238.7M

Sector

Finance

ML Signal

SELL

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

N/A

Current Price

$0.38

Market Cap

249.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ERC
OTLK
Founded
2003
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.7M
249.6M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
ERC
OTLK
Price
$8.16
$0.38
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $4.82
AVG Volume (30 Days)
89.3K
★ 3.2M
Earning Date
01-01-0001
12-18-2026
Dividend Yield
★ 8.37%
N/A
EPS Growth
N/A
★ 55.91
EPS
★ 0.72
N/A
Revenue
N/A
★ $8,146,123.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6,315.49
P/E Ratio
$11.42
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.20
$0.16
52 Week High
$9.56
$2.54

Technical Indicators

Market Signals
Indicator
ERC
OTLK
Relative Strength Index (RSI) 27.58 34.43
Support Level N/A $0.19
Resistance Level $9.20 $0.39
Average True Range (ATR) 0.12 0.04
MACD -0.03 -0.00
Stochastic Oscillator 11.11 18.07

Price Performance

Historical Comparison
ERC
OTLK

About ERC Allspring Multi-Sector Income Fund

Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: